Lumos Diagnostics Eliminates Debt After Repaying A$5 Million Loan Facility Following April Capital Raise

Lumos Diagnostics Completes Closure of A$5.0 Million Bridge Loan Initiated in September 2025

Lumos Diagnostics has officially closed the A$5.0 million secured loan facility originally established on 9 September 2025. This facility was structured as a working capital bridge to support the company during a critical phase as it pursued a Clinical Laboratory Improvement Amendments (CLIA) waiver from the U.S. Food and Drug Administration (FDA) for its FebriDx® point-of-care diagnostic test. The closure marks the conclusion of a financing arrangement lasting approximately ten months.

The loan was provided by two major shareholders, Tenmile Ventures Pty Ltd and Ryder Capital Management Pty Ltd, demonstrating their confidence during a significant regulatory process. The facility was described as a "bridge" loan, reflecting its short-term, transitional nature rather than a long-term debt instrument. Lumos has confirmed that all security interests held by the lenders under the facility have now been formally released.

Only A$1.0 Million Drawn from the A$5.0 Million Facility Before Full Repayment

Of the total A$5.0 million available, Lumos Diagnostics drew only A$1.0 million, leaving A$4.0 million undrawn throughout the facility’s term. This detail highlights that the company’s working capital needs were limited during this period and that the loan served primarily as a contingency buffer rather than a main source of operational funding.

The drawn balance of A$1.0 million plus accrued interest was fully repaid following the company’s A$20.0 million placement completed in April 2026. The repayment had been previously disclosed as a designated use of the placement proceeds, indicating this closure fulfills a planned financial obligation. The company did not specify the amount of accrued interest repaid as part of the loan closure.

April 2026 Placement Facilitated Full Loan Repayment

The repayment of the loan to Tenmile and Ryder Capital was enabled by the A$20.0 million placement completed in April 2026. Lumos had identified loan repayment as a specific use of these funds at the time of the capital raise. This placement not only strengthened Lumos’s cash position for commercial activities but also allowed the company to retire its sole debt on the Balance Sheet.

The sequence of events—from the loan’s establishment in September 2025, through the April 2026 capital raise, to the July 2026 loan closure—reflects a deliberate approach to managing the company’s balance sheet amid significant regulatory and commercial developments. While the company has not detailed how the remaining placement proceeds beyond the loan repayment are allocated, the update indicates a focus on U.S. commercialisation of FebriDx®.

Lumos Diagnostics Now Maintains a Debt-Free Financial Position

As of 2 July 2026, Lumos Diagnostics reports having no debt on its balance sheet. This contrasts with the position in September 2025 when the loan facility was established and the company carried a contingent Liability of up to A$5.0 million. The release of all lender security interests further simplifies the company’s financial structure by removing encumbrances on its Assets associated with the secured loan.

For investors, a debt-free balance sheet at this stage signals financial stability as Lumos prepares to expand commercial operations in the U.S. Operating without debt reduces financial risk and offers greater flexibility to allocate capital toward growth. However, details on the company’s cash position and Burn Rate were not included in this update; investors should consult recent financial statements for a comprehensive view of Lumos’s Liquidity.

CEO Doug Ward Highlights FebriDx® CLIA Waiver as "Transformative" for U.S. Market Entry

CEO Doug Ward acknowledged the loan closure, emphasizing the crucial support from Tenmile Ventures and Ryder Capital during a pivotal period. He stated: "The Company sincerely appreciates the financial support provided by Tenmile and Ryder Capital, with this loan provided as a bridge while Lumos progressed its application toward the transformative and successful granting of CLIA waiver for FebriDx®." Ward added that Lumos is now well-funded to close out the loan, release the security, and accelerate U.S. commercialisation of FebriDx®.

Ward’s description of the CLIA waiver as "transformative" underscores its strategic importance. The waiver from the U.S. FDA permits FebriDx® to be used in a broader range of healthcare settings—including physician offices, urgent care clinics, and pharmacies—without requiring complex laboratory infrastructure. This substantially expands the addressable U.S. market for the point-of-care diagnostic. The company confirmed the waiver has been granted but did not provide further details on its scope or timing beyond Ward’s remarks.

Tenmile Ventures and Ryder Capital’s Role as Major Shareholders and Lenders

The loan facility was provided by Tenmile Ventures Pty Ltd and Ryder Capital Management Pty Ltd, both major shareholders in Lumos Diagnostics. Their provision of a secured loan during regulatory uncertainty reflects alignment with the company’s strategic direction and confidence in the FebriDx® program. Such related-party financing arrangements are common among ASX-listed healthcare companies during capital-intensive development phases.

With the loan fully repaid and all security interests released, the financial relationship related to this facility has concluded. The company did not disclose whether Tenmile Ventures or Ryder Capital maintain any ongoing advisory, commercial, or financing roles beyond their shareholdings. Investors interested in governance aspects should review related-party disclosures from the facility’s original establishment in September 2025.

FebriDx® Technology and Its Importance for U.S. Commercial Growth

FebriDx® is Lumos Diagnostics’ flagship rapid point-of-care diagnostic test, designed to help healthcare professionals distinguish bacterial from viral infections in patients with acute respiratory symptoms. It supports antibiotic stewardship by enabling faster, more accurate clinical decisions at the point of care without laboratory processing. The U.S. market for point-of-care infectious disease diagnostics represents a significant commercial opportunity, especially amid increased focus on respiratory illness management.

The CLIA waiver, now granted, is a critical enabler for broad deployment of FebriDx® across diverse U.S. healthcare settings. With the loan facility closed and the balance sheet debt-free, Lumos aims to accelerate U.S. commercialisation. Specific strategies regarding distribution, sales force, and Revenue targets were not disclosed, and investors will likely await further updates on commercial progress in the coming months.

Implications of Loan Closure and Debt-Free Status for Lumos’s Financial Strategy

The loan closure and debt-free balance sheet indicate Lumos Diagnostics is entering its U.S. commercial phase with financial clarity. Eliminating its only debt and releasing all associated security interests simplifies its financial structure, allowing management to focus on building commercial momentum for FebriDx® in the U.S.

Investors should monitor upcoming updates on FebriDx®’s commercial traction following the CLIA waiver, including announcements on distribution deals, healthcare partnerships, or early revenue. The immediate share price impact of the loan closure was not evident at the time of writing. For a detailed understanding of Lumos’s financial trajectory, investors are encouraged to review forthcoming quarterly or half-year reports, which are expected to provide more information on cash position, expenditure, and revenue following the April 2026 capital raise.